Zimmer Biomet Reports Full Year 2025 EPS of $3.55, Achieves $710M Net Income

Zimmer Biomet Holdings (NYSE: ZBH) reported full year 2025 earnings of $3.55 per share in its latest SEC filing, capping off a year that saw the medical device manufacturer generate $710 million in net income as demand for knee and hip replacement procedures remained robust.

The Warsaw, Indiana-based company, which specializes in orthopedic implants and surgical tools, filed its quarterly results with the Securities and Exchange Commission on February 10, 2026, providing investors with a detailed look at its financial performance during a period of ongoing recovery in elective surgical procedures.

Key Numbers

The full year 2025 earnings per share of $3.55 represented solid profitability for the orthopedic device leader, with net income totaling $710 million for the twelve-month period. This performance reflected the company's ability to maintain margins despite ongoing supply chain pressures affecting the broader medical device industry.

Quarterly results showed variability throughout the year, with the third quarter delivering particularly strong results at $2.84 per share on net income of $570 million. The company also reported a separate Q3 result of $1.16 per share on $230 million in net income, while the second quarter contributed $1.68 per share on $330 million in net income.

The earnings trajectory throughout 2025 demonstrated the company's operational resilience as healthcare systems globally continued to work through surgical backlogs created during the pandemic years. The strong third-quarter performance of $2.84 per share particularly stood out, suggesting momentum in the company's core orthopedic franchises.

What Management Said

While specific management commentary was not included in the 8-K filing, the timing and structure of the earnings release indicates management's confidence in the reported results. The company's decision to file promptly on February 10, 2026, follows standard practice for timely disclosure of material financial information to shareholders.

The filing structure, which includes multiple debt securities listed on the New York Stock Exchange alongside the common stock, reflects Zimmer Biomet's diversified capital structure. The company maintains several bond issuances including 2.425% Notes due 2026, 1.164% Notes due 2027, and 3.518% Notes due 2032, indicating active management of its debt portfolio to support growth initiatives.

What to Watch

Several factors merit attention as Zimmer Biomet moves forward into 2026. The variability in quarterly earnings throughout 2025 suggests the company continues to navigate an evolving operating environment where procedure volumes can fluctuate based on hospital capacity and patient demand.

The upcoming maturity of the company's 2.425% Notes in 2026 represents a near-term refinancing opportunity that could impact the company's interest expense and capital allocation strategy. With interest rates having shifted significantly since these notes were issued, management's approach to this refinancing will be closely watched.

Investors should also monitor the company's ability to sustain the profitability levels achieved in 2025, particularly given the strong third-quarter performance. The orthopedic device market remains competitive, with pricing pressures from hospital systems and competition from both established players and innovative startups continuing to challenge margins.

The medical device sector's ongoing recovery from pandemic-related disruptions presents both opportunities and challenges. While deferred procedures have created pent-up demand, supply chain constraints and labor shortages in healthcare settings could impact the pace at which this backlog is addressed.

Zimmer Biomet's position as one of the leading orthopedic device manufacturers gives it advantages in scale and market reach, but the company must continue to innovate and execute operationally to maintain its competitive position. The 2025 results suggest the company is managing these challenges effectively, but continued vigilance will be required as market conditions evolve.

*Source: Zimmer Biomet Holdings 8-K filing with the Securities and Exchange Commission, February 10, 2026*

— StockCliff Research